Aryl halides
Apexbio Technology LLC Nintedanib (BIBF 1120) 656247-17-5 10mM (in 1mL DMSO)
Nintedanib (BIBF 1120 CAS 656247-17-5) is an orally bioavailable small-molecule tri-kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3) fibroblast growth factor receptors (FGFR1-3) and platelet-derived growth factor receptors (PDGFR / ) By inhibiting these receptor pathways at nanomolar concentrations (IC50 20 100 nmol/L) Nintedanib disrupts angiogenesis signaling and demonstrates antiangiogenic activity It is extensively investigated in preclinical and clinical research for idiopathic pulmonary fibrosis (IPF) as well as oncology including non-small-cell lung carcinoma ovarian cancer colorectal cancer and hepatocellular carcinoma
eMolecules 353-83-3 | 1-Iodo-2,2,2-trifluoroethane | Oakwood Chemical | MFCD00001082 | 209.938 | C2H2F3I | 97.000 | FC(F)(F)CI | 5g | 537662098
1-Iodo-2,2,2-trifluoroethane | Oakwood Chemical | 353-83-3 | MFCD00001082 | 209.938 | C2H2F3I | 97.000 | FC(F)(F)CI | 5g | 537662098
eMolecules 15854-87-2 | 4-iodopyridine | Pharmablock - Stock | MFCD02093937 | 204.998 | C5H4IN | 97.000 | Ic1ccncc1 | 10g | 537810607
4-iodopyridine | Pharmablock - Stock | 15854-87-2 | MFCD02093937 | 204.998 | C5H4IN | 97.000 | Ic1ccncc1 | 10g | 537810607
eMolecules 353-83-3 | 1,1,1-trifluoro-2-iodo-ethane | Pharmablock | MFCD00001082 | 209.938 | C2H2F3I | 97.000 | FC(F)(F)CI | 250mg | 800864811
1,1,1-trifluoro-2-iodo-ethane | Pharmablock | 353-83-3 | MFCD00001082 | 209.938 | C2H2F3I | 97.000 | FC(F)(F)CI | 250mg | 800864811
Medchemexpress LLC 5-iodo-A-85380 dihydrochloride hydrate | 1217837-17-6 | MFCD20488048 | 99.0% | 363.02 g/mol | C9H13Cl2IN2O | 50 MG
5-Iodo-A-85380 dihydrochloride is a research-grade, high-affinity ligand selective for α4β2 nicotinic acetylcholine receptors. Supplied as the dihydrochloride hydrate salt, it is intended for in vitro receptor binding and pharmacology studies where subtype-selective binding is required.
- Selective ligand for α4β2 and α6β2 nicotinic acetylcholine receptors.
- Very high binding affinity with reported Kd values of 12 pM (rat) and 14 pM (human).
- Supplied as the dihydrochloride hydrate salt for improved handling and stability.
- High purity (98.97%) suitable for biochemical assays.
- Molecular weight 363.02 g/mol; appropriate for molarity calculations in assays.
Medchemexpress LLC tert-Butyl 3-(2-iodoethoxy)propanoate | 2296723-16-3 | ≥95.0% | 300.13 | 250 MG
tert-Butyl 3-(2-iodoethoxy)propanoate is a PROTAC linker, which refers to the PEG composition. It can be used in the synthesis of PROTAC FAK degrader 1. This product is for research use only and not sold to patients.
- Protac linker
- Peg composition
- Used in the synthesis of PROTAC FAK degrader 1
- Appearance: liquid
- Color: colorless to light yellow
eMolecules 58142-99-7 | 5-Iodoisoquinoline | MFCD11226893 | 1g
Ambeed | 5-Iodoisoquinoline | 1g | 552568456 | A134703 | 58142-99-7 | MFCD11226893 | 255.058 | C9H6IN
If you are unable to find the chemical you are looking for, make sure you are logged into your fishersci.com account and click on the following link:
eMolecules Building Block Tool<|a>
eMolecules 1260741-78-3 | 6-Bromo-3-iodo-1-methyl-1H-indazole | Combi-Blocks, Inc.336.958 | C8H6BrIN2 | 98.000 | Cn1nc(I)c2ccc(Br)cc12 | 1g | 801094891
6-Bromo-3-iodo-1-methyl-1H-indazole | Combi-Blocks, Inc. | 1260741-78-3336.958 | C8H6BrIN2 | 98.000 | Cn1nc(I)c2ccc(Br)cc12 | 1g | 801094891
eMolecules 1260741-78-3 | 6-Bromo-3-iodo-1-methyl-1H-indazole | Combi-Blocks, Inc.336.958 | C8H6BrIN2 | 98.000 | Cn1nc(I)c2ccc(Br)cc12 | 5g | 801094892
6-Bromo-3-iodo-1-methyl-1H-indazole | Combi-Blocks, Inc. | 1260741-78-3336.958 | C8H6BrIN2 | 98.000 | Cn1nc(I)c2ccc(Br)cc12 | 5g | 801094892
Frontier Specialty Chemicals 1G 2,4-DICHLORO-5-IODOPYRIMIDI
2,4-Dichloro-5-iodopyrimidine; CAS No: 13544-44-0
Medchemexpress LLC Methylcbi-azaindole-benzamide-mom-boc-ethylenediamine-d | 2222445-87-4 | 99.7% | 859.36 | C44H51ClN6O10 | 1 MG
MethylCBI-azaindole-benzamide-MOM-Boc-ethylenediamine-D is a cleavable ADC linker used in the synthesis of antibody-drug conjugates and supplied as a high-purity research reagent for conjugation and synthetic workflows.
- Cleavable linker for intracellular release
- High purity (99.7%)
- Molecular weight 859.36 g/mol
- Available in small research quantities (1 mg and larger)
- Storage: powder at -20°C; in solvent at -80°C (6 months) or -20°C (1 month)
eMolecules 4296-15-5 | 1-Iodo-2-methoxyethane | Accela ChemBio (ASD) | MFCD07644549 | 185.992 | C3H7IO | 98.000 | COCCI | 5g | 596321489
1-Iodo-2-methoxyethane | Accela ChemBio (ASD) | 4296-15-5 | MFCD07644549 | 185.992 | C3H7IO | 98.000 | COCCI | 5g | 596321489
eMolecules 55270-33-2 | 4-Iodoisoquinoline | Combi-Blocks, Inc. | MFCD00234496 | 255.058 | C9H6IN | 97.000 | Ic1cncc2ccccc12 | 1g | 569291747
4-Iodoisoquinoline | Combi-Blocks, Inc. | 55270-33-2 | MFCD00234496 | 255.058 | C9H6IN | 97.000 | Ic1cncc2ccccc12 | 1g | 569291747
Medchemexpress LLC 6-Chloro-7-iodo-7-deazapurine | 123148-78-7 | 99.99% | C6H3ClIN3 | 5 G
6-Chloro-7-iodo-7-deazapurine is a biochemical reagent used in life science research. It serves as a biological material or organic compound and is also utilized as a pharmaceutical intermediate.
- Biochemical reagent
- Suitable for life science related research
- Used as a pharmaceutical intermediate
Apexbio Technology LLC 4-iodo-SAHA 1219807-87-0 250mg
4-iodo-SAHA (CAS 1219807-87-0) is a hydrophobic analog of suberoylanilide hydroxamic acid (SAHA) that functions as a histone deacetylase (HDAC) inhibitor targeting both class I and II HDACs By blocking HDAC activity 4-iodo-SAHA modulates the reversible acetylation of lysine residues on histone and non-histone proteins affecting transcriptional regulation In cellular assays 4-iodo-SAHA demonstrated antiproliferative effects with EC50 values of 1 1 M in SKBR3 breast cancer cells and 0 95 0 12 0 24 0 85 and 1 3 M in HT29 U937 JA16 HL60 and K562 tumor cell lines respectively Notably it exhibited greater potency than SAHA in inhibiting proliferation of U937 leukemia cells These properties make 4-iodo-SAHA valuable for investigating HDAC-related cellular processes and cancer models